Filing Details

Accession Number:
0001104659-25-014387
Form Type:
13G Filing
Publication Date:
2025-02-13 19:00:00
Filed By:
Redmile Group
Company:
Zymeworks Inc.
Filing Date:
2025-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Redmile Group, LLC 0 4,840,463 7.0%
Jeremy C. Green 0 4,840,463 7.0%
Redmile Biopharma Investments III, L.P. 0 3,470,727 5.0%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  Redmile Group, LLC's beneficial ownership of the Issuer's common shares ("Common Stock") is comprised of 4,840,463 shares of Common Stock owned by certain private investment vehicles managed by Redmile Group, LLC (collectively, the "Redmile Clients"), including Redmile Biopharma Investments III, L.P. ("RBI III"). The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on 68,877,526 shares of Common Stock outstanding as of October 30, 2024, as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2024 filed with the Securities and Exchange Commission on October 31, 2024 (the "Form 10-Q").


SCHEDULE 13G



Comment for Type of Reporting Person:  Jeremy C. Green's beneficial ownership of the Common Stock is comprised of 4,840,463 shares of Common Stock owned by certain Redmile Clients, including RBI III. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on 68,877,526 shares of Common Stock outstanding as of October 30, 2024, as reported by the Issuer in the Form 10-Q.


SCHEDULE 13G



Comment for Type of Reporting Person:  Percentage based on 68,877,526 shares of Common Stock outstanding as of October 30, 2024, as reported by the Issuer in the Form 10-Q.


SCHEDULE 13G


 
Redmile Group, LLC
 
Signature:/s/ Jeremy C. Green
Name/Title:Managing Member
Date:02/14/2025
 
Jeremy C. Green
 
Signature:/s/ Jeremy C. Green
Name/Title:Jeremy C. Green
Date:02/14/2025
 
Redmile Biopharma Investments III, L.P.
 
Signature:/s/ Jeremy C. Green
Name/Title:Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P.
Date:02/14/2025